Skip to content
10-Q

Quarterly Report

Odonate Therapeutics, Inc.

0001564590-21-027812

← back to feed
Filed
May 14, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2021 · May 7, 2021 38.51M sh
Stock Issued Q1 2021 · Mar 31, 2021 842.11K sh
Stock Issued Q1 2021 · Sep 1, 2020 5.61M sh
Capex Q1 2021 · Mar 31, 2021 $21K
Capex Q1 2021 · Mar 31, 2020 $19K
Operating Cash Flow Q1 2021 · Mar 31, 2021 −$24.91M
Operating Cash Flow Q1 2021 · Mar 31, 2020 −$27.85M
Cash And Equivalents Q1 2021 · Mar 31, 2021 $133.87M
Cash And Equivalents Q1 2021 · Dec 31, 2020 $157.98M
Cash And Equivalents Q1 2021 · Mar 31, 2020 $153.83M
Cash And Equivalents Q1 2021 · Dec 31, 2019 $181.17M
Stockholders Equity Q1 2021 · Mar 31, 2021 $105.3M
Stockholders Equity Q1 2021 · Dec 31, 2020 $136.15M
Stockholders Equity Q1 2021 · Mar 31, 2020 $135.24M
Stockholders Equity Q1 2021 · Dec 31, 2019 $162.3M
Current Liabilities Q1 2021 · Mar 31, 2021 $33.1M
Current Liabilities Q1 2021 · Dec 31, 2020 $27.07M
Total Liabilities Q1 2021 · Mar 31, 2021 $37.58M
Total Liabilities Q1 2021 · Dec 31, 2020 $31.74M
Current Assets Q1 2021 · Mar 31, 2021 $136.1M
Current Assets Q1 2021 · Dec 31, 2020 $159.87M
Total Assets Q1 2021 · Mar 31, 2021 $142.88M
Total Assets Q1 2021 · Dec 31, 2020 $167.89M
Sga Expense Q1 2021 · Mar 31, 2021 $2.89M
Sga Expense Q1 2021 · Mar 31, 2020 $2.87M
Rd Expense Q1 2021 · Mar 31, 2021 $30.93M
Rd Expense Q1 2021 · Mar 31, 2020 $27.95M
Net Income Q1 2021 · Mar 31, 2021 −$33.77M
Net Income Q1 2021 · Mar 31, 2020 −$30.16M
Operating Income Q1 2021 · Mar 31, 2021 −$33.82M
Operating Income Q1 2021 · Mar 31, 2020 −$30.82M